Vizsgálati helyszín
Brain Matters Research
Delray Beach, Florida 33445, Egyesült ÁllamokMég nincs intézményhez kötve
- 16futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 34 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis12 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Toboroz4 vizsgálat
- Leállították4 vizsgálat
- Meghívásos bevonás2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Eli Lilly and Company6 vizsgálat
- Novo Nordisk A/S4 vizsgálat
- Cassava Sciences, Inc.3 vizsgálat
- Cognito Therapeutics, Inc.3 vizsgálat
- University of Southern California3 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595· 2. fázis· Eli Lilly and Company· Forrás
Contact: Paayal Patel (principal investigator)
Toboroz
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321· 2. fázis· Lighthouse Pharmaceuticals, Inc.· Forrás
Contact: Jen Blasi
Fut, nem toboroz
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
NCT06750432· 1. fázis· ProMis Neurosciences, Inc· Forrás
Fut, nem toboroz
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· GAP Innovations, PBC· Forrás
Contact: Laura Ystha Alonso
Fut, nem toboroz
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360· 2. fázis· Weill Medical College of Cornell University· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· 2. fázis· Acumen Pharmaceuticals· Forrás
Meghívásos bevonás
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031· Cognito Therapeutics, Inc.· Forrás
Meghívásos bevonás
Alzheimer's Plasma Extension
NCT06416072· University of Southern California· Forrás
Fut, nem toboroz
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656· 2. fázis· Cognition Therapeutics· Forrás
Fut, nem toboroz
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659· 3. fázis· Eisai Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás
Fut, nem toboroz
Multi-Center Study of Sensory Stimulation to Improve Brain Function
NCT03556280· Cognito Therapeutics, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836· 2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Lezárult
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
NCT05891496· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
NCT05637801· Cognito Therapeutics, Inc.· Forrás
Leállították
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· 3. fázis· Eli Lilly and Company· Forrás
Leállították
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· 3. fázis· Biogen· Forrás
Leállították
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
NCT05352763· 2. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
NCT04381468· 1/2. fázis· Vaccinex Inc.· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
NCT04388254· 2. fázis· Cassava Sciences, Inc.· Forrás
Leállították
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· 3. fázis· Biogen· Forrás
Lezárult
TRC-PAD Program: In-Clinic Trial-Ready Cohort
NCT04004767· University of Southern California· Forrás
Lezárult
Memory Improvement Through Nicotine Dosing (MIND) Study
NCT02720445· 2. fázis· University of Southern California· Forrás
Hibát jelzek